Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk

Authors Ajikumar V Aryangat, John E Gerich

Published Date March 2010 Volume 2010:6 Pages 145—155

DOI http://dx.doi.org/10.2147/VHRM.S8216

Published 9 March 2010

Ajikumar V Aryangat, John E Gerich
University of Rochester, Rochester, New York, USA
Abstract: Hyperglycemia is a major risk factor for both the microvascular and macrovascular complications in  patients with type 2 diabetes. This review summarizes the cardiovascular results of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with particular emphasis on postprandial hyperglycemia, in adverse cardiovascular outcomes in patients with type 2 diabetes. Treatment options, including the new dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 mimetics that primarily target postprandial hyperglycemia, are also discussed. Hyperglycemia increases cardiovascular mortality, and reducing hyperglycemia lowers cardiovascular risk parameters. Control of both fasting and postprandial hyperglycemia is necessary to achieve optimal glycated hemoglobin control. Therefore, antihyperglycemic agents that preferentially target postprandial hyperglycemia, along with those that preferentially target fasting hyperglycemia, are strongly suggested to optimize individual diabetes treatment strategies and reduce complications.
Keywords: postprandial hyperglycemia, diabetes mellitus, drugs, cardiovascular risk

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Readers of this article also read:

Interleukin 10-coated nanoparticle systems compared for molecular imaging of atherosclerotic lesions

Almer G, Summers KL, Scheicher B, Kellner J, Stelzer I, Leitinger G, Gries A, Prassl R, Zimmer A, Mangge H

International Journal of Nanomedicine 2014, 9:4211-4222

Published Date: 3 September 2014

Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo

Xiang DX, Zheng Y, Duan W, Li XJ, Yin JJ, Shigdar S, O'Connor ML, Marappan M, Zhao XJ, Miao YQ, Xiang B, Zheng CL

International Journal of Nanomedicine 2013, 8:4103-4114

Published Date: 30 October 2013

Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation

Zhao L, Wei Y, Huang Y, He B, Zhou Y, Fu J

International Journal of Nanomedicine 2013, 8:3769-3779

Published Date: 2 October 2013

Interleukin-12 prevents colorectal cancer liver metastases in mice

Shen F, Li JL, Cai WS, Zhu GH, Gu WL, Jia L, Xu B

OncoTargets and Therapy 2013, 6:523-526

Published Date: 13 May 2013

Biocompatibility of magnetic Fe3O4 nanoparticles and their cytotoxic effect on MCF-7 cells

Chen DZ, Tang QS, Li XD, Zhou XJ, Zang J, Xue WQ, Xiang JY, Guo CQ

International Journal of Nanomedicine 2012, 7:4973-4982

Published Date: 14 September 2012

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo

Vascular Health and Risk Management 2010, 6:671-690

Published Date: 5 August 2010

The interleukin-6 –174 G/C promoter polymorphism and arterial stiffness; the Rotterdam Study

Mark PS Sie, Francesco US Mattace-Raso, André G Uitterlinden, Pascal P Arp, Albert Hofman, et al

Vascular Health and Risk Management 2008, 4:863-869

Published Date: 7 September 2008

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes

Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christian Lerch

Vascular Health and Risk Management 2008, 4:753-768

Published Date: 4 September 2008